enow.com Web Search

  1. Ad

    related to: benlysta

Search results

  1. Results from the WOW.Com Content Network
  2. Belimumab - Wikipedia

    en.wikipedia.org/wiki/Belimumab

    Belimumab, sold under the brand name Benlysta, is a human monoclonal antibody that inhibits B-cell activating factor (BAFF), [6] also known as B-lymphocyte stimulator (BLyS). [7] It is approved in the United States [ 8 ] and Canada, [ 9 ] and the European Union [ 5 ] to treat systemic lupus erythematosus and lupus nephritis.

  3. A Bad Year for the 6,300% Miracle - AOL

    www.aol.com/news/2011-12-30-a-bad-year-for-the...

    In March, after the Food and Drug Administration approved lupus drug Benlysta, Human Genome Sciences (NAS: HGSI) hit a multiyear high. From the low of below $0.50, the biotech soared some 6,300%.

  4. B-cell activating factor - Wikipedia

    en.wikipedia.org/wiki/B-cell_activating_factor

    Belimumab (Benlysta) is a monoclonal antibody developed by Human Genome Sciences and GlaxoSmithKline, with significant discovery input by Cambridge Antibody Technology, which specifically recognizes and inhibits the biological activity of B-Lymphocyte stimulator (BLyS) and is in clinical trials for treatment of Systemic lupus erythematosus and ...

  5. List of therapeutic monoclonal antibodies - Wikipedia

    en.wikipedia.org/wiki/List_of_therapeutic...

    Benlysta: mab: human: B-cell activating factor (BAFF) Y: systemic lupus erythematosus without renal or CNS involvement Bemarituzumab [26] mab: humanized: FGFR2: gastric cancer or gastroesophageal junction adenocarcinoma Benralizumab [38] Fasenra: mab: humanized: CD125: Y: asthma Berlimatoxumab [26] mab: human: Staphylococcus aureus bi-component ...

  6. Slow and Steady Has Investors Fleeing - AOL

    www.aol.com/news/2012-02-28-slow-and-steady-has...

    Slow and steady might win the race, but it isn't a way to keep biotech investors' interest. As we approach a year after GlaxoSmithKline (NYS: GSK) and Human Genome Sciences' (NAS: HGSI) Benlysta ...

  7. Down 20%: Benylsta Not Ramping Fast Enough - AOL

    www.aol.com/news/2011-10-26-down-20-benylsta-not...

    Sales of Human Genome Sciences' (NAS: HGSI) new lupus drug Benylsta continues to grow -- just not fast enough to keep investors interest. The stock traded down more than 20% today after net sales ...

  8. Cambridge Antibody Technology - Wikipedia

    en.wikipedia.org/wiki/Cambridge_Antibody_Technology

    CAT was also behind belimumab, the anti-BlyS antibody drug marketed as Benlysta and the first new approved drug for systemic lupus in more than 50 years. [1] In 2018, the Nobel Prize organisation awarded one quarter of the Nobel Prize in Chemistry to a founding member of CAT, Sir Greg Winter FRS "for the phage display of peptides and antibodies ...

  9. Benlysta - Wikipedia

    en.wikipedia.org/?title=Benlysta&redirect=no

    From or to a drug trade name: This is a redirect from (or to) the trade name of a drug to (or from) the international nonproprietary name (INN).

  1. Ad

    related to: benlysta